



Non-Executive Director Appointment

MELBOURNE — 30 July 2018 — Imagion Biosystems Limited (ASX: IBX) (**Imagion** or the **Company**) is pleased to confirm the formal appointment of Dr John Hazle (Professor and Chair of the Department of Imaging Physics at The University of Texas MD Anderson Cancer Center) as Non-Executive Director of the Company, effective today 30 July 2018.

As previously advised, the formal appointment of Dr John Hazle as Director was subject to approval from MD Anderson Cancer Center's Conflict of Interest Committee, which has now been obtained. John will Chair the company's Scientific Advisory Board.

An Appendix 3X (Initial Director's Interest Notice) in relation to Dr Hazle is attached.

-ENDS

About Imagion Biosystems

Imagion Biosystems is at the crossroads of biotechnology and nanotechnology. Its novel bioimaging and nanomagnetic detection systems have been developed specifically to detect cancer and other diseases earlier and with higher specificity than is currently possible. With MagSense™ technology, the company has the potential to optimize patient care and reduce mortality rates across various cancer indications. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations:

Matt Wright, NWR Communications
matt@nwrcommunications.com.au
+61-451-896-420

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity Imagion Biosystems Limited
ACN 616 305 027

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John HAZLE
Date of appointment	30 July 2018

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
150,000 Performance Rights, which are subject to ASX escrow restrictions for 24 months from official quotation. The Performance Rights are issued under the Company's Long Term Incentive Plan, and will each vest into an ordinary share 24 months after official quotation

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Number & class of Securities
	Nil

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.